Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

September 27, 2017

Primary Completion Date

October 8, 2019

Study Completion Date

October 8, 2019

Conditions
Carcinoma, Renal Cell
Interventions
DRUG

Sunitinib

Patients randomized to sunitinib schedule 4/2 will receive sunitinib at 50 mg daily for 4 weeks on, followed by 2 weeks off, per standard of care. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline, 4 weeks and 12 weeks.

DRUG

Sunitinib

Patients randomized to sunitinib schedule 2/1 will receive sunitinib 50 mg daily for 2 weeks on, followed by 1 week off. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline, 5 weeks and 12 weeks.

Trial Locations (1)

27705

Duke Cancer Institute, Durham

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Duke University

OTHER